Neostigmine Methylsulfate — 5MG, Injection, carton of 10 × 10 mL vials

Neostigmine Methylsulfate — 5MG, Injection, carton of 10 × 10 mL vials

Neostigmine Methylsulfate is a injection for intravenous use. Neostigmine Methylsulfate Injection, USP is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Neostigmine Methylsulfate Injection, USP, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

• Active ingredient or product type: NEOSTIGMINE METHYLSULFATE
• Strength/concentration: 5MG
• Dosage form and route: Injection, Intravenous
• Exact package presentation: carton of 10 × 10 mL vials
• NDC/item number: 0641-6150-10
• Manufacturer: HIKMA PHARMACEUTICALS USA INC
• Storage/handling: stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light. Store in carton until time of use.
• Status: Rx only

Important safety information: Bradycardia: Atropine or glycopyrrolate should be administered prior to Neostigmine Methylsulfate Injection, USP to lessen risk of bradycardia. ( 5.1 ) Serious Reactions with Coexisting Conditions: Use with caution in patients with coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome or myasthenia gravis. ( 5.2 ) Neuromuscular Dysfunction: Can occur if large doses of Neostigmine Methylsulfate Injection, USP are administered when neuromuscular blockade is minimal; reduce d

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.